valiltramiprosate

Valiltramiprosate is an oral, synthetic valine-conjugated prodrug of tramiprosate (also known as homotaurine), developed for the treatment of Alzheimer's disease. After oral administration, it is rapidly converted to tramiprosate and 3-sulfopropanoic acid, both of which are active agents that inhibit the formation of neurotoxic amyloid-beta (Aβ) oligomers in the brain. The drug works by binding to Aβ42 monomers and stabilizing their native conformation, thereby preventing aggregation into toxic oligomers—a key driver in Alzheimer’s disease pathology. Valiltramiprosate was designed to improve upon tramiprosate by offering better oral absorption, more consistent pharmacokinetics, and reduced gastrointestinal side effects. It is being developed primarily for early-stage Alzheimer’s disease in patients who are carriers of the APOE4 allele. Clinical trials have shown reductions in plasma biomarkers associated with AD and preservation of brain structure on MRI[1][7][8].

Brand names

ALZ-801ALZ801ALZ 801

Other names

tramiprosate prodrughomotaurine prodrug